USFDA21 Aug 2026, 07:10 pm
Caplin Point Subsidiary Receives 10 Observations from USFDA Inspection
AI Summary
Caplin Point Laboratories Ltd announced that its subsidiary, Caplin Steriles Limited, has completed an unannounced inspection by the United States Food and Drug Administration (US FDA) at its injectable and ophthalmic manufacturing facility in Gummidipoondi. The inspection, conducted from August 13 to August 21, 2026, resulted in the company receiving Form 483 with 10 observations. Caplin Point stated that these observations are procedural and do not pertain to data integrity, nor were they repeat observations. The company is actively addressing these points and will submit its response to the US FDA within the stipulated timeframe.
Key Highlights
- Caplin Steriles facility inspected by US FDA.
- Received Form 483 with 10 procedural observations.
- Observations do not relate to data integrity.
- Company is addressing observations and will respond.
- No repeat observations were noted.
Price Impact
More from CAPLIPOINT